V.N. MUKHAMADIEVA^1, 3, N.G. SHAMSUTDINOVA^1, 2, T.YU. NURIAKHMETOVA¹, D.I. ABDULGANIEVA^1, 2

 ¹Kazan State Medical University, Kazan

²Republic Clinical Hospital, Kazan

³City Clinical Hospital No. 7 named after M.N. Sadykov, Kazan

 Contact details:

Mukhamadieva V.N. — post-graduate student of the Department of Hospital Therapy

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-987-403-54-07, e-mail: venera.mukhamadieva@yandex.ru

The purpose — to conduct a comparative analysis of the course of post-COVID syndrome in patients with rheumatoid arthritis and spondyloarthritis.

Material and methods. The study included 140 patients: 91 patients (65%) with rheumatoid arthritis (RA) and 49 (35%) with spondyloarthritis (SpА). The presence of post-COVID syndrome, RA and SpA activity were assessed and risk factors for exacerbations of major diseases were identified 3, 6, 9, 12 months after COVID-19.

Results. The incidence of post-COVID syndrome among patients with RA was 73.7%, among patients with SрA — 61.3%. Most often, patients with RA and SpA reported fatigue, and/or muscle pain, and/or headaches, and/or dysautonomia, and/or cognitive impairment 87.3% and 71%, respectively, increased joint pain — the second most common complaint — 81.6% and 65.1%, respectively. Patients with RA had more frequent and longer complaints characteristic of post-COVID syndrome compared to patients with SpA. The maximum value of activity in RA, AS, and PsA was revealed 3 months after COVID-19. Among patients with RA, the main factors influencing the frequency of exacerbations after 3 months were cardiovascular diseases, female gender, viral lung damage, RA activity before NCI, COVID-19 symptoms; among patients with PsA: exacerbation of PsA before COVID-19, initial glucocorticosteroid therapy, COVID-19 symptoms; among patients with AS: symptoms of COVID-19.

Conclusions. Among patients with RA, regardless of the severity of COVID-19, post-COVID syndrome was more common compared with patients with SpA. The largest number of patients in exacerbation was recorded 3 months after the COVID-19. The largest number of risk factors for exacerbations at 3 months after COVID-19 was recorded among patients with RA and PsA; among patients with AS, only the symptoms of COVID-19 were affected.

Key words: post-COVID syndrome, rheumatoid arthritis, spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, asthenia, arthralgia, rheumatic disease activity.

REFERENCES

1. Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep, 2021, vol. 11 (1), rr. 16144.
2. Cañas C.A. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med. Hypotheses, 2020, vol. 145, pp. 110345.
3. Ong S.W.X., Fong S.-W., Young B.E. et al. Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients. Open Forum Infect. Dis, 2021, vol. 8, p. ofab156.
4. Phetsouphanh C., Darley D.R., Wilson D.B. et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol, 2022, vol. 23, pp. 210–216.
5. Taams L.S., Steel K.J.A., Srenathan U. et al. IL-17 in the immunopathogenesis of spondyloarthritis. Nat. Rev. Rheumatol, 2018, vol. 14, pp. 453–466.
6. Seeßle J., Waterboer T., Hippchen T., Simon J., Kirchner M., Lim A. et al. Merle Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin. Infect. Dis, 2022, vol. 74 (7), pp. 1191–1198.
7. Dewanjee S., Kandimalla R., Kalra R.S., Valupadas C., Vallamkondu J., Kolli V. et al. Reddy COVID-19 and rheumatoid arthritis crosstalk: emerging association, therapeutic options and challenges. Cells, 2021, vol. 10 (12), p. 3291.
8. Petersen M.S., Paleoudis E., Bari D. et al. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS One, 2020, vol. 15 (12), p. e0243882.
9. Gianfrancesco M., Hyrich K.L., Al-Adely S. et al. COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis, 2020, vol. 79 (7), pp. 859–866.
10. Aronova E.S., Belov B.S., Gridneva G.I. COVID-19 in patients with rheumatoid arthritis: course and outcomes. Effektivnaya farmakoterapiya, 2023, vol. 19, no. 29, pp. 34–40 (in Russ.).
11. Abdurakhmanova N. Quality of life in patients with ankylosing spondyloarthritis after covid-19. J. Biomed. Pract, 2022, vol. 7 (2), pp. 95–101.
12. Pastor Navarro S., Ibáñez Martínez M., Compán Fernández O., Miguel Ibáñez B., Martínez González O., Hidalgo Calleja C. et al. Persistent post-Covid symptoms in psoriatic arthritis patients. Arthritis Rheumatol, 2022, vol. 74 (9).
13. Prikaz Ministerstva zdravookhraneniya Rossiyskoy Federatsii ot 01.07.2021 no. 698n “Ob utverzhdenii Poryadka napravleniya grazhdan na prokhozhdenie uglublennoy dispanserizatsii, vklyuchaya kategorii grazhdan, prokhodyashchikh uglublennuyu dispanserizatsiyu v pervoocherednom poryadke” (zaregistrirovan 07.07.2021 no. 64157) [Order of the Ministry of Health of the Russian Federation dated 01.07.2021 No. 698n “On approval of the Procedure for referring citizens for in-depth medical examination, including categories of citizens undergoing in-depth medical examination on a priority basis” (registered on 07.07.2021 No. 64157)].
14. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand, 1983, vol. 67 (6), pp. 361–370. DOI: 10.1111/j.1600-0447.1983.tb09716.x
15. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry, 1960, vol. 23 (1), pp. 56–62. DOI: 10.1136/jnnp.23.1.56
16. Zolotovskaya I.A., Shatskaya P.R., Davydkin I.L., Shavlovskaya O.A. Asthenic syndrome in patients who have had COVID-19. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova, 2021, no. 121 (4), pp. 25–30 (in Russ.). DOI: 10.17116/jnevro202112104125
17. Kratkaya shkala otsenki psikhicheskogo statusa (MMSE) [Mini-Mental State Examination (MMSE)], available at: https://memini.ru/tests/23789/ (accessed on: 23.01.2022).